Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Denise Hoffman

Physician Assistant Kingston, PA Physician Assistant

NPI 1821458217 CMS profile 10726203

423 3Rd Ave, Suite B, Kingston, PA 18704

Open in the dashboard

General payments

$7,901

406 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Denise Hoffman of Kingston, PA is reported in the CMS Open Payments database as having received $7,901 across 406 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,456 63
2024 General $1,412 70
2023 General $1,821 106
2022 General $1,622 88
2021 General $1,590 79

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Denise Hoffman
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Denise Hoffman were reported at $1,456. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Denise Hoffman Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,590 $132 $37–$438 $132
2022 $1,622 $155 $48–$522 $149
2023 $1,821 $167 $52–$557 $160
2024 $1,412 $178 $55–$600 $164
2025 $1,456 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Astellas Pharma US Inc $1,326 69 payments
  2. Sumitomo Pharma America, Inc. $1,270 69 payments
  3. Janssen Biotech, Inc. $951 52 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $881 34 payments
  5. AbbVie, Inc. $806 47 payments
  6. Pfizer Inc. $461 27 payments
  7. Urovant Sciences Inc $420 24 payments
  8. Medtronic, Inc. $314 19 payments
  9. ConvaTec Inc. $248 7 payments
  10. Dentsply Ih AB $173 5 payments
  11. Other $1,050 53 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,472 401 payments
  2. Education $429 5 payments
Products named General payments · program years 2021–2025
  1. GEMTESA $1,690 93 payments
  2. XTANDI $872 47 payments
  3. ERLEADA $767 41 payments
  4. Nubeqa $706 31 payments
  5. MYRBETRIQ $522 38 payments
  6. Xofigo $493 19 payments
  7. LUPRON DEPOT $353 25 payments
  8. ORGOVYX $339 20 payments
  9. INTERSTIM $314 19 payments
  10. BOTOX $296 14 payments
  11. Other $2,212 107 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

1,907

Median for Physician Assistant: 241

Drug cost

$414,511

Median for Physician Assistant: $4,110

Branded share of claims

41.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 226 $170,829
Myrbetriq Mirabegron Brand 232 $162,531
Elmiron Pentosan Polysulfate Sodium Brand 21 $16,988
Estradiol Generic 89 $6,304
Tamsulosin Hcl Generic 255 $5,398
Potassium Citrate Er Potassium Citrate Brand 48 $5,157
Premarin Estrogens, Conjugated Brand 12 $4,936
Solifenacin Succinate Generic 144 $4,908
Fesoterodine Fumarate Er Fesoterodine Fumarate Brand 25 $4,678
Tolterodine Tartrate Er Tolterodine Tartrate Brand 35 $4,185

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$119,436

Of which drugs: $34,648

Medicare patients

823

Average age 77

Services billed

3,254

398 women, 425 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Ischemic heart disease 35%
Diabetes 32%
Chronic kidney disease 25%
Cancer 25%
Atrial fibrillation 21%
Depression 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 31 214 $29,785

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GEMTESA
  • Sumitomo Pharma America, Inc. $392
$392 226 —
Nubeqa
  • Bayer HealthCare Pharmaceuticals Inc. $217
$217 — —
XTANDI
  • Astellas Pharma US Inc $118
  • PFIZER INC. $33
$151 — —
LUPRON DEPOT
  • AbbVie, Inc. $65
$65 — 214
BOTOX
  • AbbVie, Inc. $63
$63 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

406 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record